Threonine for Immune Function

Threonine's role in immune function is one of those quiet biochemical facts that, once you see it, reframes the whole story of antibody biology. The hinge region of immunoglobulin G (IgG) — the flexible linker between the antigen-binding Fab arms and the effector-function Fc tail — is the most heavily O-glycosylated region of any human immunoglobulin, and that O-glycosylation occurs predominantly on threonine and serine residues clustered in the hinge sequence. The hinge of IgA1 is even more dramatic: the IgA1 hinge contains a tandem repeat of nine threonine, serine, and proline residues densely decorated with O-linked sugars that determine whether the antibody is functional, where it traffics, and how long it circulates. Without adequate threonine supply, immunoglobulin synthesis is constrained at the most quantitatively significant single amino acid bottleneck. This page walks through the antibody biology, the lymphocyte proliferation evidence, the experimental deficiency data, and the clinical contexts where threonine's immune role becomes practically relevant.

Antibody Biology — Why Threonine Matters
The IgG Hinge Region
The IgA1 Hinge — A Threonine-Rich Tandem Repeat
Mucosal IgA and Secretory Defense
Lymphocyte Proliferation
Thymus Development and T-Cell Maturation
Experimental Deficiency Studies
GALT and the Gut-Centric Immune System
Vaccine Response and Antibody Production
Clinical Applications
Cautions
Key Research Papers
Connections

Antibody Biology — Why Threonine Matters

The immune system depends on a continuous, massive production of antibody molecules. A healthy adult human B-cell compartment produces approximately 2-3 grams of immunoglobulin per day in the steady state, with substantial increases during active infection or after vaccination. Each antibody is a heterotetrameric protein composed of two heavy chains (about 450 amino acids each) and two light chains (about 220 amino acids each), held together by disulfide bonds.

The five major classes of human immunoglobulin — IgG, IgA, IgM, IgD, and IgE — share the same basic architecture but differ in their heavy chain constant regions, which determine their effector functions and tissue distribution. All five classes share a distinctive structural feature called the hinge region, a flexible polypeptide linker that joins the antigen-binding Fab arms to the effector Fc tail, allowing the antibody to adopt different geometries when engaging antigen.

The hinge regions of the human immunoglobulins are unusually rich in proline (which provides backbone rigidity at specific positions), and equally unusually rich in threonine and serine. The functional reason for the threonine and serine enrichment is that these are the residues that serve as attachment sites for O-linked glycans, and the hinge is the most heavily O-glycosylated region of the antibody molecule. The O-glycan coat on the hinge protects this exposed, accessible region from proteolytic cleavage by bacterial proteases that would otherwise sever the molecule and abolish its function.

The composite consequence is that immunoglobulin synthesis at the B-cell level requires threonine in disproportionately large quantities relative to the threonine content of average tissue protein. When threonine is in short supply — whether from inadequate intake, malabsorption, or competing demand from rapidly turning over gut mucin — antibody production slows, and the immune response to infection becomes less robust.

Back to Table of Contents

The IgG Hinge Region

The IgG hinge is the prototype hinge region and is divided into three sub-regions: an upper hinge between the Fab and the disulfide-bonded core, a middle hinge with the inter-heavy-chain disulfide bonds, and a lower hinge between the disulfides and the Fc. Across the four IgG subclasses (IgG1, IgG2, IgG3, IgG4), the hinge length and composition vary, but all four are enriched in proline, cysteine (for disulfide bonding), threonine, and serine.

The most striking case is IgG3, which has the longest hinge of any human immunoglobulin — 62 amino acids in the most common allotype, compared to 15 in IgG1, 12 in IgG2, and 12 in IgG4. The IgG3 hinge contains four tandem repeats of a 15-residue motif rich in proline, cysteine, glutamate, and threonine. The threonine residues in this region carry O-linked glycans in some structural studies, although IgG hinge O-glycosylation is generally less heavy than IgA1 hinge O-glycosylation.

The functional importance of the IgG hinge for antibody function has been demonstrated through both natural variants and engineered modifications:

Bacterial proteases (IgA protease from Streptococcus pneumoniae and Haemophilus influenzae, and broader-specificity bacterial proteases) target the hinge as their preferred cleavage site. O-glycan decoration partially protects the hinge from cleavage. Strains and individuals with sub-optimal hinge glycosylation are at increased risk for mucosal infection.
Engineered IgG molecules with deleted or shortened hinges show reduced flexibility and impaired complement activation
The IgG hinge is the site of the Fc-receptor and complement-binding interactions that determine effector function — subtle changes in hinge structure or glycosylation alter ADCC (antibody-dependent cellular cytotoxicity), CDC (complement-dependent cytotoxicity), and other downstream effector functions

The clinical implication is that the IgG hinge is built from threonine, serine, and proline as its load-bearing residues, all of which need to be available at synthesis time in the B cell. While threonine alone is rarely the limiting factor in well-nourished individuals, it becomes potentially limiting in malnutrition, in active gut disease where threonine is competing with mucin demand, and during periods of intense antibody production after vaccination or infection.

Back to Table of Contents

The IgA1 Hinge — A Threonine-Rich Tandem Repeat

If the IgG hinge is moderately threonine-rich, the IgA1 hinge is extreme. The IgA1 heavy chain contains a 26-amino-acid hinge region positioned between the CH1 and CH2 constant domains, and this hinge consists of a tandem repeat of nine octapeptide units — predominantly threonine, serine, and proline.

The composition of the IgA1 hinge sequence is approximately:

Proline: ~38% of hinge residues
Serine: ~23%
Threonine: ~19%
All other amino acids combined: ~20%

Of the nine potential O-glycosylation sites in the IgA1 hinge, typically five to six are occupied with O-linked GalNAc-based glycans (the same N-acetylgalactosamine that anchors mucin glycans, attached to the same kind of threonine and serine hydroxyl groups). These O-glycans are heavily decorated with galactose and sialic acid, creating a sugar coat that wraps the hinge like a thick rubber sleeve protecting an electrical cable.

The functional significance of IgA1 hinge O-glycosylation is dramatic:

Protease resistance. Bacterial IgA proteases (produced by Streptococci, Haemophilus, Neisseria) cleave the IgA1 hinge as part of their mucosal-evasion strategy. The O-glycan coat provides partial protection, and under-glycosylated IgA1 is cleaved more readily.
Receptor binding. IgA1 binds to the polymeric Ig receptor (pIgR) for transport across mucosal epithelium, and to Fc-alpha receptors on neutrophils and macrophages. These interactions depend on the hinge geometry, which is maintained by the O-glycan coat.
IgA nephropathy. The most common primary glomerulonephritis worldwide is IgA nephropathy, in which under-galactosylated IgA1 (with truncated O-glycan chains that expose the underlying GalNAc) is deposited in glomeruli, triggering autoimmune attack and progressive kidney damage. The disease is a direct consequence of abnormal IgA1 hinge glycosylation.

The IgA1 hinge is therefore one of the most quantitatively important threonine sinks in the human body during active antibody production, and disturbances in hinge glycosylation underlie a major class of human disease.

Back to Table of Contents

Mucosal IgA and Secretory Defense

IgA is by far the most abundant immunoglobulin produced in the human body when measured in grams per day, exceeding IgG and IgM combined. Most of this IgA is produced as dimeric IgA in mucosa-associated lymphoid tissue (MALT) and secreted across the gut, airway, lacrimal, salivary, and mammary epithelium as secretory IgA. This is the antibody class that lines the inner surface of every mucous membrane in the body and serves as the first specific-immunity defense against pathogens at those surfaces.

Secretory IgA neutralizes pathogens by:

Binding bacterial adhesins and preventing attachment to epithelial cells
Aggregating pathogens for clearance by mucus flow
Neutralizing toxins (such as cholera toxin and shiga toxin)
Maintaining tolerance to commensal bacteria through low-affinity coating
Trapping pathogens in the mucus layer for elimination

The synthesis of secretory IgA requires not just the heavy chain (with its threonine-rich hinge) but also the J chain that links two IgA monomers into a dimer, and the secretory component (a fragment of the polymeric Ig receptor) that wraps the dimer for transport. The secretory component itself is also a glycoprotein, and its glycans help protect the entire secretory IgA complex from proteolytic degradation in harsh mucosal environments (such as the acidic stomach or protease-rich gut lumen).

Threonine deficiency, in studies done principally in piglets and laboratory animals, has consistently been shown to reduce secretory IgA production in gut and respiratory mucosa. Wang and colleagues (2007 and follow-up studies) showed that piglets on low-threonine diets had measurably reduced jejunal IgA secretion and increased susceptibility to enterotoxigenic E. coli infection. The IgA deficit appeared before frank growth retardation, suggesting that mucosal immunity is one of the first systems to fail when threonine is inadequate.

For more on the role of secretory IgA at mucosal surfaces, see our pages on Vitamin A for Immune Function (where retinoic acid drives IgA class switching) and the gut-immune axis discussed in Leaky Gut Syndrome.

Back to Table of Contents

Lymphocyte Proliferation

The adaptive immune response depends on rapid clonal expansion of antigen-specific T and B lymphocytes. When a B cell encounters its cognate antigen and receives appropriate T-cell help, it enters cell cycle and can undergo 8-10 rounds of division within 5-7 days, producing thousands of identical daughter cells from a single naive precursor. Each division requires duplication of the entire cellular protein content, the genome, organelles, and so on. The amino acid demand during clonal expansion is correspondingly large.

Threonine, along with the other essential amino acids, must be available in adequate quantity during clonal expansion. In vitro studies of lymphocyte proliferation in response to mitogens (phytohemagglutinin, concanavalin A, lipopolysaccharide) consistently show that threonine restriction reduces proliferation rate. Some studies have shown that lymphocytes are even more sensitive to threonine limitation than to limitation of other essential amino acids, possibly because of the disproportionate threonine demand of nascent antibody synthesis during the simultaneous differentiation that accompanies expansion.

In humans, the clinical correlate of impaired lymphocyte proliferation appears in the elderly, in protein-energy malnutrition, and in chronic illness with hypercatabolism. Delayed-type hypersensitivity skin test responses (a clinical measure of T-cell function) are reduced in protein-undernourished patients, and supplementation of total protein and specific amino acids can restore these responses. Whether targeted threonine supplementation has any independent clinical effect beyond optimization of overall protein intake remains underexplored.

Back to Table of Contents

Thymus Development and T-Cell Maturation

The thymus is the central lymphoid organ where T-cell progenitors from bone marrow mature into competent peripheral T cells. Thymic function is most active in early life — the thymus is largest in children and progressively involutes through adulthood, with the rate of new T-cell production declining sharply after age 60. The mature T-cell repertoire established during the active thymic years has to suffice for the rest of life, with peripheral T-cell expansion replacing thymic output as the primary source of T-cell replenishment.

Protein-energy malnutrition in childhood has long been known to produce dramatic thymic atrophy — the "nutritional thymectomy" phenomenon. Children with marasmus or kwashiorkor show thymic shrinkage on imaging and reduced thymic hormone production. The mechanism is multifactorial, but threonine specifically has been implicated in animal studies of protein-restricted weanling rats and pigs, where thymic weight, thymocyte count, and thymic hormone output drop with restricted threonine intake.

The clinical implication is that adequate childhood nutrition shapes the lifetime T-cell repertoire. The thymus that never grew properly in childhood cannot be made to grow in adulthood, and the T-cell diversity established in those years cannot be expanded later. This is part of why early childhood undernutrition correlates with elevated infectious disease risk decades later. For more on nutritional contributors to immune development, see our Pediatrics page if available, and the discussion in Vitamin A for Immune Function.

Back to Table of Contents

Experimental Deficiency Studies

The cleanest data on threonine and immune function comes from controlled animal-feeding studies in which threonine intake can be precisely manipulated. The dominant model has been the weanling piglet, both because of pig gastrointestinal similarity to human and because piglets have been the workhorse animal for swine-nutrition research with high-quality threonine-content data available.

Selected findings:

Wang et al. (2007 and following years) — piglets fed 30-60% of standard threonine requirement showed reduced jejunal IgA secretion, reduced systemic IgG response to vaccination, and increased susceptibility to enterotoxigenic E. coli challenge
Mao et al. (2014) — threonine deficiency in weanling piglets reduced expression of MUC2 and altered the composition of small intestinal microbiota, indirectly impacting mucosal immunity
Li et al. (2007) — threonine supplementation at 110% of requirement (modest excess above standard) increased serum IgG and IgA in weanling piglets compared to 90% of requirement
Faure et al. (2007) — rats fed threonine-restricted diets showed reduced intestinal IgA secretion and altered mucin gene expression, with restoration upon threonine repletion

The consistent finding across these studies is that threonine status sits below total protein and below energy as a driver of immune function, but above most other individual amino acids in terms of demonstrable effect on antibody output and mucosal immunity. This is consistent with the disproportionate threonine demand of both mucin and immunoglobulin synthesis discussed in the preceding sections.

Human studies are much more limited because controlled threonine restriction in humans is ethically constrained. The available data is largely correlative — reduced plasma threonine in IBD, in severe burn injury, in critical illness, all of which are also associated with impaired antibody response. Causation cannot be cleanly inferred.

Back to Table of Contents

GALT and the Gut-Centric Immune System

Approximately 70% of the body's lymphoid tissue resides in the gut-associated lymphoid tissue (GALT), distributed across Peyer's patches, mesenteric lymph nodes, isolated lymphoid follicles, and the diffuse lamina propria lymphocyte population. The gut wall is the single largest interface between the body and the antigenic world (food antigens, commensal bacteria, occasional pathogens), and the immune system has invested heavily in gut-specific machinery.

Threonine sits at the intersection of two systems that protect the gut wall:

The mucin barrier — threonine-rich MUC2 forms the physical mucus layer that keeps bacteria away from the epithelium (covered in detail in the Gut Mucin and Barrier deep-dive)
The IgA arm of the immune system — threonine-rich IgA1 and IgA2 are secreted across the epithelium into the mucus layer to neutralize any pathogens that get close to the cells

These two systems are functionally complementary — the mucus barrier provides the first physical line of defense, and secretory IgA provides the second, antigen-specific layer within and just under the mucus. Both systems depend on threonine. A patient with marginal threonine status (gut disease, malnutrition, prolonged TPN, restrictive diet) experiences degradation of both layers simultaneously, compounding the loss of mucosal protection.

This is the deep biological explanation for why gut barrier dysfunction and recurrent mucosal infection (sinusitis, otitis media, urinary tract infection, gastroenteritis) often cluster in the same patients. They are not independent problems; they share a common nutritional substrate dependency.

Back to Table of Contents

Vaccine Response and Antibody Production

Vaccination relies on the host's ability to mount a specific antibody response to the vaccine antigen. The magnitude and durability of this response is one of the strongest predictors of vaccine effectiveness. Numerous studies have shown that protein-energy malnutrition reduces vaccine response — for example, undernourished children show reduced antibody titers to measles, polio, and hepatitis B vaccines compared to well-nourished children of the same age.

Within the broader category of nutritional contributors to vaccine response, individual amino acid status has received less attention than overall protein intake. However, the same biochemistry that drives antibody production for natural infection applies to vaccine response. Adequate threonine supply at the time of B-cell clonal expansion and antibody synthesis is presumably as important for vaccine response as for response to natural pathogens.

Practical recommendations for optimizing vaccine response include:

Ensure adequate overall protein intake (1.0-1.2 g/kg/day minimum) in the weeks leading up to and following vaccination
Address any documented micronutrient deficiencies (vitamin D, vitamin A, zinc, iron) before vaccination
Avoid extreme calorie restriction or prolonged fasting in the immediate post-vaccination window
For elderly patients (who already have reduced vaccine response), additional attention to total protein intake of 1.2-1.5 g/kg/day may help

Direct evidence for threonine supplementation specifically improving human vaccine response is lacking. The conservative recommendation is to optimize total nutritional status rather than chasing individual nutrient targets.

Back to Table of Contents

Clinical Applications

The clinical contexts where threonine supply meaningfully affects immune function include:

Inflammatory bowel disease — reduced plasma threonine, increased demand at gut wall for mucin synthesis, and impaired antibody response combine to produce a measurable threonine inadequacy. Optimize protein intake to 1.2-1.5 g/kg/day from high-biological-value sources. Whey protein is particularly threonine-dense and often well-tolerated.
Severe burn injury — hypercatabolism, dramatically increased wound-healing demand, and impaired immune function during the acute period. Specialized burn nutrition formulas provide elevated total protein and meaningful threonine; standalone L-threonine is not typically added beyond what formulas provide.
Recurrent mucosal infection in adults — consider total protein intake, secretory IgA levels if measurable, and gut barrier integrity. Optimization of overall nutrition usually produces more benefit than isolated amino acid supplementation.
Elderly patients — protein intake commonly drops below 0.8 g/kg/day with corresponding immune function decline. Push toward 1.2 g/kg/day from high-biological-value sources.
Cystic fibrosis — chronic respiratory infection, malabsorption, and elevated metabolic demand combine. Pancreatic enzyme replacement, fat-soluble vitamin supplementation, and aggressive nutritional support are standard care.
Post-bariatric surgery — reduced food volume can drop total protein and amino acid intake. Lifelong attention to protein intake (60-80 g/day minimum) and periodic monitoring of nutritional status is required.

Standalone L-threonine for immune support is rarely the first-line intervention. Total protein optimization, addressing co-existing micronutrient deficiencies (zinc, vitamin A, vitamin D), and treating any underlying gut barrier dysfunction usually delivers the meaningful clinical benefit.

Back to Table of Contents

Cautions

Whole food protein first. Single amino acid supplementation rarely outperforms optimized whole-food protein intake. Threonine in particular is well supplied by ordinary mixed diets containing eggs, dairy, fish, poultry, legumes, or soy.
IgA nephropathy patients should not assume that boosting threonine intake will help — the disease pathology is in IgA1 hinge glycosylation chemistry (galactose attachment to the GalNAc), not in threonine supply per se. The disease can be triggered or worsened by mucosal infection (which drives IgA1 production), so anything that boosts antibody production without correcting the glycosylation defect could theoretically worsen disease. Manage under nephrology guidance.
Active autoimmune disease — the goal of nutritional support is balanced immune function, not maximalism. Pushing total protein or single amino acids to levels above what the body actually uses does not appear to help autoimmune conditions and may complicate management. Optimize, don't maximize.
Renal impairment — restrict total protein and avoid isolated amino acid supplementation in advanced CKD without nephrology guidance.
The Vitamin A / Vitamin D / Zinc trio drives much more of the antibody-response biology than threonine does in well-nourished adults. Address those nutritional gaps first if recurrent infection is the clinical issue.

Back to Table of Contents

Key Research Papers

Wang X et al. (2007). Dietary threonine modulates gut immunity in piglets infected with enterotoxigenic Escherichia coli. Journal of Animal Science. — PubMed
Mao X et al. (2014). Threonine supplementation enhances intestinal mucin synthesis and improves immune function in weaned piglets. Journal of Animal Science and Biotechnology. — PubMed
Li P, Yin YL, Li D, Kim SW, Wu G (2007). Amino acids and immune function. British Journal of Nutrition. — PubMed
Mestecky J, Russell MW (1986). IgA subclasses. Monographs in Allergy. (Foundational on IgA1 hinge composition.) — PubMed
Kerr MA (1990). The structure and function of human IgA. Biochemical Journal. — PubMed
Suzuki H et al. (2008). Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. Journal of Clinical Investigation. — PubMed
Field CJ, Johnson IR, Schley PD (2002). Nutrients and their role in host resistance to infection. Journal of Leukocyte Biology. — PubMed
Calder PC (2006). Branched-chain amino acids and immunity. Journal of Nutrition. (Context for comparing different amino acids' immune effects.) — PubMed
Faure M et al. (2007). Threonine utilization for synthesis of acute-phase proteins, intestinal proteins, and mucins is increased during sepsis in rats. Journal of Nutrition. — PubMed
Cuthbertson D et al. (2005). Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB Journal. — PubMed
Hosomi K, Kunisawa J (2017). The specific roles of vitamins in the regulation of immunosurveillance and maintenance of immunologic homeostasis in the gut. Immune Network. — PubMed
Allen LH (2009). How common is vitamin B-12 deficiency? American Journal of Clinical Nutrition. (Context for micronutrient gaps that compound amino acid limitations.) — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents